COPD & Lung Disease: cell-therapy evidence by therapy class
Across every stem-cell intervention, ClinicalTrials.gov holds 34 registered records for COPD & Lung Disease — 10 recruiting, 2 at Phase 3 or 4, in 10 countries. Snapshot 2026-08-29.
The condition, and why cells are proposed
COPD combines airflow obstruction, emphysematous tissue loss and chronic inflammation. Cell approaches target inflammation and possibly alveolar repair; destroyed alveolar architecture does not regrow, so the realistic ambition is slowing decline and reducing exacerbations rather than restoring lung tissue.
Therapy classes side by side
| Therapy class | Registered | Recruiting | Phase 3/4 | Countries |
|---|---|---|---|---|
| MSC | 10 | 4 | 1 | 7 |
| HSCT | 2 | 2 | 0 | 2 |
| exosomes | 1 | 1 | 0 | 1 |
| PRP | 3 | 0 | 0 | 2 |
Counts come from separate registry queries per class; a study testing two interventions can appear in more than one row, so rows do not sum to the all-interventions total.
Geography of the research
United States accounts for about 49% of country mentions among sampled studies; 10 countries host at least one site.
| Country | Studies with a site there |
|---|---|
| United States | 17 |
| China | 4 |
| Brazil | 3 |
| France | 2 |
| Vietnam | 2 |
| Taiwan | 2 |
| Honduras | 2 |
| Indonesia | 1 |
The largest registered studies
Sorted by planned enrolment — size is not quality, but a 300-participant trial can answer questions a 12-participant series cannot.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT03899298 — Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions | Phase 1 | Not Yet Recruiting | 5,000 | R3 Stem Cell | 2019-09-01 |
| NCT01953523 — Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions | n/a | Completed | 3,000 | Elliot Lander | 2013-09-02 |
| NCT03040674 — An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease | n/a | Completed | 489 | Lung Institute | 2017-01-03 |
| NCT03044431 — Autologous Stem Cell Treatment for Chronic Lung Disease Study | n/a | Completed | 207 | Lung Institute | 2016-04-01 |
| NCT00826683 — Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Completed | 140 | University Hospital, Limoges | 2009-03 |
| NCT02341326 — Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD | n/a | Completed | 111 | Weill Medical College of Cornell University | 2014-07 |
Most recently registered
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07477600 — cfMSC Stem Cell Therapy Targeting COPD | n/a | Not Yet Recruiting | n/a | Shenzhen Geno-Immune Medical Institute | 2027-06-30 |
| NCT07355868 — Treatment of Chronic Obstructive Pulmonary Disease (COPD) by REGEND007 Cell Therapy | n/a | Recruiting | n/a | Regend Therapeutics | 2026-03-19 |
| NCT07441226 — Umbilical Cord Mesenchymal Stem Cells as Adjuvant Therapy in Group E COPD Patients | n/a | Recruiting | n/a | RSUP Persahabatan | 2025-08-08 |
| NCT06986070 — Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD). | n/a | Recruiting | n/a | SMSbiotech | 2025-06-13 |
| NCT06946953 — REGEND001 Autologous Basal Layer Stem Cell Transplantation for Chronic Obstructive Pulmonary Disease (COPD): A Translational Application Study | n/a | Recruiting | n/a | Ruijin Hospital | 2025-03-23 |
Reading this honestly
These figures describe effort, not outcome. Published results, with their control arms and endpoints, are where benefit is decided. For COPD & Lung Disease specifically, the practical question is which registered study — if any — matches the product a provider is offering, and what its outcome measures actually are.
Frequently asked
How many stem-cell trials exist for COPD & Lung Disease?
34 registered records mention a stem-cell intervention for this condition (2026-08-29 snapshot), of which 10 were recruiting.
Which therapy class is furthest along for COPD & Lung Disease?
Ranked by Phase 3/4 records: MSC (1), HSCT (0), exosomes (0), PRP (0).
Does a recruiting trial mean I can be treated?
No. Trials have eligibility criteria, and joining one is not the same as buying a treatment. Paying a clinic for an unproven intervention outside a registered study gives you neither the protections nor the data collection of a trial.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.